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Abstract 
Review on HDAC2, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: EC 3.5.1.98, HD2, RPD3, YAF1 
HGNC (Hugo): HDAC2 
Location: 6q21 
DNA/RNA 
Description 
The HDAC2 gene is composed of 14 exons that 
span 35.029 bp of genomic DNA. 
Transcription 
The length of the transcribed mRNA is about 6659 
bp. 
Pseudogene 
No pseudogene has been described. 
Protein 
Description 
There are two proteins variants of 488 and 582 aa 
due to distinct pre-mRNA splicing events.  
The N-terminal tail of the protein contains the 
catalytic domain that comprises most of the protein. 
The N-terminal domain also has a HDAC 
association domain (HAD) essential for homo- and 
heterodimerization.  
A coiled-coil domain essential for protein-protein 
interactions is present at the C-terminal tail. It also 
contains three phosphorylation sites at Ser394, 
Ser422 and Ser424, and two S-nitrosylation sites at 
Cys262 and Cys274. 
Expression 
Widely expressed. 
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Localisation 
Nucleus. 
Function 
HDAC2 belongs to class I histone deacetylases that 
also comprise HDAC1, HDAC3 and HDAC8. 
HDAC2 acts as a transcriptional repressor through 
the desacetylation of lysine residues present at the 
N-terminal tail of histone proteins (H2A, H2B, H3 
and H4). HDAC2 heterodimerise with HDAC1, but 
the heterodimer cannot bind to DNA, so they have 
to be recruited by transcription factors such as 
YY1, SP1/SP3, the tumor suppressor genes p53 and 
BRCA1. HDAC2 can also be tethered to DNA as a 
part of the multiprotein corepressor complexes 
CoREST, mSin3 and NuRD. These complexes are 
targeted to specific genomic sequences by 
interactions with sequence-specific transcription 
factors. For example, the HDAC2/HDAC1 
containing Sin3-SAP corepressor complex is 
recruited by E2F family of transcription factors to 
repress transcription. HDAC2 containing 
complexes are also implicated in gene transcription-
regulation mediated by nuclear receptors. These 
complexes also contain other epigenetic modifier 
genes, such as methyl-binding proteins (MeCp2), 
the DNA methyl transferases DNMT1, DNMT3A 
and DNMT3B, the histone methyl transferases 
SUVAR39H1 and G9a and histone demethylases 
(LSD1), providing another way by which HDAC2 
regulates gene expression and chromatin 
remodelling. 
HDAC2 also regulates gene expression through the 
deacetylation of specific transcription factors that 
includes STAT3 and SMAD7. 
HDAC2 is a key regulator of genes regulating cell 
cycle, apoptosis, cell adhesion and migration. 
Together with HDAC1, HDAC2 regulates the 
transcription of genes implicated in haematopoiesis, 
epithelial cell differentiation, heart development 
and neurogenesis. Montgomery et al. (2007) find 
that HDAC2 and HDAC1 double-null mice show 
an uncontrolled ventricular proliferation, while 
Trivedi and collegues (2007) show the lack of 
cardiac hypertrophy in HDAC2 mutant mice. 
HDAC2 is also a key regulator of nervous system 
function acting as a repressor of synaptic plasticity 
genes that regulates learning and memory 
formation. HDAC2-deficient mouse have enhanced 
memory formation. 
Homology 
The histone deacetylase domain of HDAC2 is 
highly homologous to other class I HDACs 
(HDAC1, HDAC3 and HDAC8) showing the 
greater homology with HDAC1. This domain is 
also highly conserved between species (from yeast 
to human). 
Mutations 
Germinal 
No germinal mutations have been found. 
Somatic 
HDAC2 is mutated in sporadic tumors with 
microsatellite instability and in tumors arising in 
individuals with hereditary non-polyposis colorectal 
carcinoma. This mutation consists in a deletion of a 
nine adenines repeat present in Exon1 that produce 
a truncated and inactive form of the protein. The 
expression of the mutant form of HDAC2 induces 
resistance to the proapoptotic and antiproliferative 
effects of HDAC inhibitors. The lack of HDAC2 
expression and function produces the up-regulation 
of tumor-growth promoting genes. 
Implicated in 
Various cancers 
Note 
The deregulation of HDAC2 expression and 
activity has been linked to cancer development. 
HDAC2 is overexpressed in different tumor types 
including colon, gastric, cervical, prostate 
carcinoma, non-small cell lung cancer, and 
hepatocellular carcinoma. HDAC2 overexpression 
is implicated in cancer partly through its aberrant 
recruitment and consequent silencing of tumor 
suppressor genes. The repression of the tumor 
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suppressor gene WAF1 ID: 139> is associated with 
histone hypoacetylation at the promoter region and 
can be reversed by the treatment with HDAC 
inhibitors. 
Prognosis 
HDAC2 expression is correlated with poor 
prognosis and advanced stage disease in colorectal, 
prostate, gastric and hepatocellular carcinomas. 
Colon cancer 
Note 
There are a number of studies showing HDAC2 
overexpression in colon cancer.  
The increase of HDAC2 expression has been found 
at the protein and mRNA level indicating that 
HDAC2 overexpression is due to transcriptional 
activation.  
These studies indicate that in this tumor type 
HDAC2 transcription is regulated by beta-catenin-
TCF-myc signaling pathway that is deregulated in 
colon cancer.  
HDAC2 overexpression is correlated with poor 
prognosis and advanced stage disease in colorectal 
carcinoma.  
However, Ropero et al., found an inactivating 
mutation of HDAC2 in colon cancers with 
microsatellite instability. 
Breast cancer 
Note 
Different studies show an important role of HDAC2 
in breast cancer.  
HDAC2 Knockdown induces senescence in breast 
cancer cells.  
Moreover the loss of HDAC2 activity potentiates 
the apoptotic effect of tamoxifen in 
estrogen/progesterone positive breast cancer cells. 
Prostate cancer 
Note 
Weichert et al., found that HDAC2 was strongly 
expressed in more than 70% of prostate cancer 
cases analyzed.  
The increase in HDAC2 expression was associated 
with enhanced tumor cell proliferation and poor 
prognosis in prostate cancer suggesting HDAC2 as 
a novel prognostic factor in this tumor type. 
Hepatocellular carcinoma 
Note 
HDAC2 regulated cell cycle and disruption of 
HDAC2 caused G1/S arrest in cell cycle.  
In G1/S transition, targeted-disruption of HDAC2 
selectively induced the expression of (INK4A) ID: 
146> and p21(WAF1/Cip1), and simultaneously 
suppressed the expression of cyclin D1, CDK4 and 
CDK2.  
Consequently, HDAC2 inhibition led to the down-
regulation of E2F/DP1 target genes through a 
reduction in phosphorylation status of pRb protein. 
Gastric cancer 
Note 
HDAC2 is aberrantly up-regulated in gastric 
cancers.  
HDAC2 inactivation significantly reduced cell 
motility, cell invasion, clonal expansion, and tumor 
growth. HDAC2 knockdown-induced G(1)-S cell 
cycle arrest and restored activity of p16(INK4a) and 
the proapoptotic factors. 
Lung cancer 
Note 
HDAC2 is highly up-regulated in lung cancer. 
HDAC2 inactivation resulted in regression of tumor 
cell growth and activation of cellular apoptosis via 
p53 and Bax activation and Bcl2 suppression.  
In cell cycle regulation, HDAC2 inactivation 
caused induction of p21WAF1/CIP1 expression, and 
simultaneously suppressed the expressions of cyclin 
E2, cyclin D1, and CDK2, respectively. 
Consequently, this led to the hypophosphorylation 
of pRb protein in G1/S transition and thereby 
inactivated E2F/DP1 target gene transcriptions of 
A549 cells. HDAC2 directly regulated p21WAF1/CIP1 
expression in a p53-independent manner. 
Chronic obstructive pulmonary 
disease (COPD) 
Note 
Reduced HDAC2 activity and expression is found 
in chronic obstructive pulmonary disease (COPD). 
The reduced activity of HDAC2 produces the 
upregulation of genes implicated in the 
inflammatory response and resistance to 
corticosteroids in COPD. 
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